An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

NCT00201357 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hormone-refractory Prostate Cancer

Interventions

DRUG: Thalidomide (THADO)

Sponsor

National Health Research Institutes, Taiwan